MEET ROBERT BURTON
Rob Burton is an international engagement and regulatory specialist with extensive business expertise in Pharmaceutical Development, Tobacco Harm Reduction, Global Nicotine Regulation and the Emerging Medical & Consumer Cannabinoid market.
Rob jointly formed The Disruptive Business Partnership with his former CEO (Tim) following the development of a close working relationship whilst both at Nerudia, (acquired by Imperial Brands in 2017).
During this time Rob was Director of Science and led the global science and regulatory development for innovations across Vape, Oral Nicotine, Heated Tobacco and CBD, which included a period of time based in Washington D.C. where he was responsible for developing the company’s FDA multi-platform engagement strategy.
Prior to this role, Rob was based in America with US-based electronic cigarette company White Cloud, where, for three years, he headed up Corporate and Regulatory Affairs. Rob joined White Cloud, after five years with British American Tobacco, where he was Group Head of Public Health and Scientific Affairs leading a team of industry respected scientists focused upon delivering BAT’s Global external scientific engagement.
Before joining BAT in 2008, he spent over 20 years working in the pharmaceutical sector for AstraZeneca and SmithKline Beecham (GSK). During this time, Rob held several international commercial and scientific roles, including Global Commercial Director for Respiratory Products with AstraZeneca as well as General Manager and Area Director for Eastern European markets with both SmithKline Beecham and AstraZeneca. Whilst fulfilling these positions, Rob has spent over 12 years living in the USA, Sweden, Czech Republic and Estonia.
Burton has also held non-executive roles with several biotech start-up companies and regularly consults in both Commercial and Regulatory disciplines in the UK and Europe via his company Vesper Solutions Ltd.
He currently holds positions on the Advisory and Scientific Boards for Cannabis For Children (a US not-for-profit organisation), is an Advisory Board member for Blossom Genetics and is a Director and Board Member of AAN Medical. Rob is a member of the Medical Cannabis Clinicians Society.
An industrial chemist by training, Rob began his career working in the laboratories of Reckitt & Coleman, before moving into sales and marketing functions within Beecham’s UK.